GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includ...

British drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 billion paymen...

The acquisition gives GSK access to camlipixant, which is in late-stage development for the first-line treatment of adult patients with ref...

BC Asia Investments X Ltd is indirectly held by Bain Capital Investors LLC (Bain Private Equity), Bain Capital Credit Member LLC and Bain C...

The unlisted entity has brands like Sensodyne toothpaste, Crocin analgesic and Iodex pain balm. The majority of GSK Consumer’s India portfo...

After the deal, GSK will have a majority controlling equity interest of 68 per cent in the combined consumer healthcare business.

The global Opiates market holds good potential and the addition of GSK’s Opiates business will strengthen Sun's positioning further, says A...

The acquisition will give Sun a product portfolio consisting of poppy-derived opiate raw material — mainly used to make painkillers.

The collaboration between the two will create a new world-leading consumer healthcare business with $10 billion in annual sales.

The Cabinet Committee on Economic Affairs has approved the proposal of GlaxoSmithKline Pte Limited, Singapore for acquisition of 24.33 per ...

GSK said that it was looking to buy a 24% stake in the pharmaceuticals subsidiary for about $1billion or Rs 6,400 crore.

"I think it is wholly reasonable for a country that is having a tremendous growth with challenges has to think about pricing," Witty said.

GSK will not pay exorbitant price to buy Indian companies as it is under no such compulsions, a top company executive said.

Global pharma giant GlaxoSmithKline is eyeing acquisitions worth $ 2 billion in India, the world's fastest-growing drug market, media repor...

Witty said that Cos need to find fresh solutions to tackle issues like affordability, access & escalating research costs

Glaxosmithkline (GSK) Consumer Healthcare has announced that it wants to acquire nutritional and over-the-counter (OTC) brands, technologie...

The pharma major is close to making key acquisitions in healthcare and OTC and launch new products.